HK1254731A1 - 用於醫學應用的3-(1，2，4-***並[4，3-a]吡啶-3-基乙炔基)-4-甲基-n-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺的新型結晶鹽形式 - Google Patents

用於醫學應用的3-(1，2，4-***並[4，3-a]吡啶-3-基乙炔基)-4-甲基-n-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺的新型結晶鹽形式

Info

Publication number: HK1254731A1
Authority: HK; Hong Kong
Prior art keywords: methyl; ylethynyl; methylpiperazin; triazolo; trifluoromethylphenyl
Prior art date: 2016-04-18

Application number

HK18113742.4A

Other languages

English (en)

Inventor

G‧G‧赤樂維

I‧Y‧提托維

Original Assignee

融合制藥有限責任公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-18

Filing date

2018-10-26

Publication date

2019-07-26

2018-10-26 Application filed by 融合制藥有限責任公司 filed Critical 融合制藥有限責任公司

2019-07-26 Publication of HK1254731A1 publication Critical patent/HK1254731A1/zh

Links

KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
150000003839 salts Chemical group 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

HK18113742.4A 2016-04-18 2018-10-26 用於醫學應用的3-(1，2，4-***並[4，3-a]吡啶-3-基乙炔基)-4-甲基-n-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺的新型結晶鹽形式 HK1254731A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
RU2016114904A RU2652992C2 (ru)	2016-04-18	2016-04-18	Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения
PCT/RU2017/050025 WO2017184032A1 (en)	2016-04-18	2017-04-18	Novel crystalline salt forms of 3-(1,2,4-triazolo[4,3-a]pyridine-3-ylethynyl)-4-methyl-n-(4-((4-methylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)benzamide for medical application

Publications (1)

Publication Number	Publication Date
HK1254731A1 true HK1254731A1 (zh)	2019-07-26

Family

ID=60116178

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18113742.4A HK1254731A1 (zh)	2016-04-18	2018-10-26	用於醫學應用的3-(1，2，4-***並[4，3-a]吡啶-3-基乙炔基)-4-甲基-n-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺的新型結晶鹽形式

Country Status (17)

Country	Link
US (1)	US11225474B2 (zh)
EP (1)	EP3445763B1 (zh)
JP (1)	JP6463874B2 (zh)
KR (1)	KR101929725B1 (zh)
CN (1)	CN108473492B (zh)
AU (1)	AU2017254345A1 (zh)
BR (1)	BR112018071498A2 (zh)
CA (1)	CA3021306C (zh)
DK (1)	DK3445763T3 (zh)
EA (1)	EA032865B1 (zh)
ES (1)	ES2906048T3 (zh)
HK (1)	HK1254731A1 (zh)
IL (1)	IL262368A (zh)
PL (1)	PL3445763T3 (zh)
RU (1)	RU2652992C2 (zh)
UA (1)	UA124627C2 (zh)
WO (1)	WO2017184032A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2652992C2 (ru)	2016-04-18	2018-05-04	Общество С Ограниченной Ответственностью "Фьюжн Фарма"	Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения
RU2664420C1 (ru) *	2017-10-31	2018-08-17	Общество С Ограниченной Ответственностью "Фьюжн Фарма"	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ДОЗИРОВКА И СПОСОБ ЛЕЧЕНИЯ Ph+ ЛЕЙКЕМИЙ
CN112505131B (zh) *	2020-11-11	2023-01-13	山东省计量科学研究院	一甲基砷溶液标准物质的定值及其量值溯源方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101885722B (zh) *	2010-07-01	2013-07-24	中国科学院广州生物医药与健康研究院	杂环炔苯类化合物及其药用组合物和应用
RU2477772C2 (ru)	2011-05-20	2013-03-20	Государственное образовательное учреждение высшего профессионального образования "Саратовский государственный технический университет"	Устройство для бестраншейной прокладки трубопроводов способом прокола
RU2477723C2 (ru)	2011-06-16	2013-03-20	Общество С Ограниченной Ответственностью "Фьюжн Фарма"	Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CN103420977B (zh) *	2012-05-16	2016-06-22	上海医药集团股份有限公司	具有抗肿瘤活性的乙炔衍生物
CN103848829B (zh) *	2012-11-28	2017-04-12	南京圣和药业股份有限公司	杂芳基炔烃化合物及其应用
GB2522226A (en) *	2014-01-17	2015-07-22	Agency Science Tech & Res	Heteroaryl alkyne derivatives and uses thereof
CN104250253B (zh) *	2014-09-12	2017-04-05	辽宁大学	取代四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
RU2652992C2 (ru)	2016-04-18	2018-05-04	Общество С Ограниченной Ответственностью "Фьюжн Фарма"	Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения

2016
- 2016-04-18 RU RU2016114904A patent/RU2652992C2/ru active
- 2016-06-01 EA EA201600487A patent/EA032865B1/ru unknown
2017
- 2017-04-18 BR BR112018071498-4A patent/BR112018071498A2/pt active Search and Examination
- 2017-04-18 KR KR1020187008765A patent/KR101929725B1/ko active IP Right Grant
- 2017-04-18 US US16/094,790 patent/US11225474B2/en active Active
- 2017-04-18 UA UAA201811310A patent/UA124627C2/uk unknown
- 2017-04-18 PL PL17786237T patent/PL3445763T3/pl unknown
- 2017-04-18 EP EP17786237.2A patent/EP3445763B1/en active Active
- 2017-04-18 CN CN201780003746.XA patent/CN108473492B/zh active Active
- 2017-04-18 JP JP2018522977A patent/JP6463874B2/ja active Active
- 2017-04-18 CA CA3021306A patent/CA3021306C/en active Active
- 2017-04-18 WO PCT/RU2017/050025 patent/WO2017184032A1/en active Application Filing
- 2017-04-18 AU AU2017254345A patent/AU2017254345A1/en not_active Abandoned
- 2017-04-18 DK DK17786237.2T patent/DK3445763T3/da active
- 2017-04-18 ES ES17786237T patent/ES2906048T3/es active Active
2018
- 2018-10-14 IL IL262368A patent/IL262368A/en unknown
- 2018-10-26 HK HK18113742.4A patent/HK1254731A1/zh unknown

Also Published As

Publication number	Publication date
EP3445763A1 (en)	2019-02-27
WO2017184032A1 (en)	2017-10-26
JP6463874B2 (ja)	2019-02-06
JP2018530598A (ja)	2018-10-18
PL3445763T3 (pl)	2022-02-28
AU2017254345A1 (en)	2018-11-22
CA3021306A1 (en)	2017-10-26
US11225474B2 (en)	2022-01-18
KR20180037289A (ko)	2018-04-11
BR112018071498A2 (pt)	2019-02-19
CA3021306C (en)	2023-05-16
CN108473492B (zh)	2020-01-07
IL262368A (en)	2018-11-29
DK3445763T3 (da)	2022-01-31
ES2906048T3 (es)	2022-04-13
UA124627C2 (uk)	2021-10-20
RU2016114904A (ru)	2017-10-23
US20200325131A1 (en)	2020-10-15
RU2652992C2 (ru)	2018-05-04
KR101929725B1 (ko)	2018-12-14
EA032865B1 (ru)	2019-07-31
EP3445763B1 (en)	2021-11-10
EA201600487A1 (ru)	2017-10-31
EP3445763A4 (en)	2019-12-04
CN108473492A (zh)	2018-08-31

Similar Documents

Publication	Publication Date	Title
HK1253029A1 (zh)	2019-06-06	作為毒蕈碱性受體4(m4)拮抗劑用於治療神經系統疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相關化合物
IL274488A (en)	2020-06-30	Crystal forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
DK3699181T3 (da)	2023-03-20	Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
IL254132B (en)	2020-02-27	A solid preparation of N-(4-(1(2,6-difluorobenzyl)-5-))dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxy-1,2,3 4-tetrahydrothiano[2,3-d]pyrimidine-6-yl)phenyl)-n-methoxyurea or its salt
BR112014028395A2 (pt)	2017-06-27	derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
PH12016502461A1 (en)	2017-03-06	N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
WO2014093583A3 (en)	2014-08-07	Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof
IL287030A (en)	2021-12-01	New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy
HK1254731A1 (zh)	2019-07-26	用於醫學應用的3-(1，2，4-***並[4，3-a]吡啶-3-基乙炔基)-4-甲基-n-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺的新型結晶鹽形式
IL279101A (en)	2021-01-31	Salts of spiafatrin are accepted in pharmacies
HK1259405A1 (zh)	2019-11-29	N-[5-(3，5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氫吡喃-4-基氨基)-苯甲酰胺的新晶型
IL271399A (en)	2020-01-30	Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
PL3827004T3 (pl)	2024-01-29	Pochodne 4-(1,3,4-oksadiazol-2-ilo)pirydyn-2(1h)-onu jako inhibitory deacetylazy histonowej 6 (hdac6) do leczenia np. zakażeń
ZA201804843B (en)	2019-09-25	Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide
DK3083627T3 (da)	2019-01-02	[1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
EP3373931A4 (en)	2019-04-03	HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
HK1259249A1 (zh)	2019-11-29	抑制蛋白激酶活性化合物的晶型及其應用
ZA202003028B (en)	2021-08-25	Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
EA201891430A1 (ru)	2018-11-30	Твердые формы замещенных 5,6-дигидро-6-фенилбензо[f]изохинолин-2-аминовых соединений
IL288158A (en)	2022-01-01	Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
EP3807254A4 (en)	2022-03-23	HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
EP3750905A4 (en)	2021-12-15	SALT OF HETEROCYCLIC COMPOUND SUBSTITUTED BY PYRANOSIS, PROCESS FOR PREPARATION AND USE
IL249428A0 (en)	2017-02-28	A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's
HUE063662T2 (hu)	2024-01-28	Helyettesített piridiniloxibenzol, sói és gyomirtó hatóanyagként való alkalmazása
ZA201808625B (en)	2019-08-28	Crystalline form of compound suppressing protein kinase activity, and application thereof